MA31880B1 - Formulations stables d'un derive thiadiazole - Google Patents

Formulations stables d'un derive thiadiazole

Info

Publication number
MA31880B1
MA31880B1 MA32616A MA32616A MA31880B1 MA 31880 B1 MA31880 B1 MA 31880B1 MA 32616 A MA32616 A MA 32616A MA 32616 A MA32616 A MA 32616A MA 31880 B1 MA31880 B1 MA 31880B1
Authority
MA
Morocco
Prior art keywords
tiadiazole
derivative
stable formulations
dimethyl
ethanesulfonylamino
Prior art date
Application number
MA32616A
Other languages
Arabic (ar)
English (en)
Inventor
Hiroko Kusano
Dinesh Shyamdeo Mishra
Yoshikazu Tashiro
Yosuke Watanabe
Hong Zhuang
Original Assignee
Lilly Co Eli
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31880(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Kyowa Hakko Kogyo Kk filed Critical Lilly Co Eli
Publication of MA31880B1 publication Critical patent/MA31880B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des paramètres de formulation et des conditions de fabrication de compositions pharmaceutiques stables comprenant du n-{4-(2,2-diméthyl-propionyl)- (5r)-5- [(2-éthylamino-éthanesulfonylamino) -méthyl]-5-phényl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-diméthyl- propionamide qui réduisent au minimum la conversion chirale indésirable vers la forme énantiomère s moins active.
MA32616A 2007-07-12 2010-02-11 Formulations stables d'un derive thiadiazole MA31880B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94926807P 2007-07-12 2007-07-12
PCT/US2008/069301 WO2009009470A1 (fr) 2007-07-12 2008-07-07 Formulations stables de dérivé du thiadiazole

Publications (1)

Publication Number Publication Date
MA31880B1 true MA31880B1 (fr) 2010-12-01

Family

ID=39735000

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32616A MA31880B1 (fr) 2007-07-12 2010-02-11 Formulations stables d'un derive thiadiazole

Country Status (28)

Country Link
US (1) US8222284B2 (fr)
EP (1) EP2178508B1 (fr)
JP (1) JP4875205B2 (fr)
KR (1) KR101188036B1 (fr)
CN (1) CN101730525A (fr)
AR (1) AR067472A1 (fr)
AU (1) AU2008275258A1 (fr)
BR (1) BRPI0814039A2 (fr)
CA (1) CA2694277C (fr)
CL (1) CL2008001996A1 (fr)
CO (1) CO6270304A2 (fr)
CR (1) CR11210A (fr)
DO (1) DOP2010000004A (fr)
EA (1) EA016861B1 (fr)
EC (1) ECSP109864A (fr)
ES (1) ES2401477T3 (fr)
GT (1) GT201000003A (fr)
HK (1) HK1141238A1 (fr)
IL (1) IL202382A0 (fr)
MA (1) MA31880B1 (fr)
MX (1) MX2010000468A (fr)
NZ (1) NZ581791A (fr)
PE (1) PE20090438A1 (fr)
SV (1) SV2010003449A (fr)
TN (1) TN2010000015A1 (fr)
TW (1) TW200918050A (fr)
UA (1) UA97672C2 (fr)
WO (1) WO2009009470A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150404A1 (fr) 2009-06-26 2010-12-29 三菱電機株式会社 Compresseur à réfrigérant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454903B9 (fr) 2001-12-11 2011-10-05 Kyowa Hakko Kirin Co., Ltd. Dérivés de thiadiazoline pour le traitement du cancer
ES2377498T3 (es) * 2003-04-18 2012-03-28 Kyowa Hakko Kirin Co., Ltd. Inhibidor de quinesina en etapa M
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
EP1870404A4 (fr) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd Agent pour le traitement d'une tumeur hématopoïétique
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
EP1908755A4 (fr) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd Agent thérapeutique contre la resténose

Also Published As

Publication number Publication date
AU2008275258A1 (en) 2009-01-15
KR101188036B1 (ko) 2012-10-05
ECSP109864A (es) 2010-03-31
TW200918050A (en) 2009-05-01
KR20100029827A (ko) 2010-03-17
SV2010003449A (es) 2010-08-10
CA2694277A1 (fr) 2009-01-15
CO6270304A2 (es) 2011-04-20
JP2010533190A (ja) 2010-10-21
TN2010000015A1 (en) 2011-09-26
EA016861B1 (ru) 2012-08-30
JP4875205B2 (ja) 2012-02-15
CL2008001996A1 (es) 2009-05-22
UA97672C2 (ru) 2012-03-12
MX2010000468A (es) 2010-04-09
US8222284B2 (en) 2012-07-17
US20110009458A1 (en) 2011-01-13
EA201070136A1 (ru) 2010-06-30
HK1141238A1 (en) 2010-11-05
CN101730525A (zh) 2010-06-09
PE20090438A1 (es) 2009-04-18
EP2178508B1 (fr) 2013-02-06
AR067472A1 (es) 2009-10-14
BRPI0814039A2 (pt) 2017-10-03
CR11210A (es) 2010-06-23
EP2178508A1 (fr) 2010-04-28
ES2401477T3 (es) 2013-04-19
GT201000003A (es) 2012-03-13
IL202382A0 (en) 2010-06-30
CA2694277C (fr) 2013-04-09
WO2009009470A1 (fr) 2009-01-15
DOP2010000004A (es) 2010-03-15
NZ581791A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA30765B1 (fr) Derives innovants du thiophene
EA200800817A1 (ru) Пестицидные производные бифениламидина
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
WO2005115392A8 (fr) 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides utilises comme modulateurs des recepteurs de la chimiokine
EA200702198A1 (ru) Фармацевтические составы
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
WO2007023507A3 (fr) Composition a activite antimicrobienne supportant des oxazolidinones ainsi que procedes de preparation associes
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
WO2007058862A3 (fr) Composes d’imidazolidinone utiles en tant qu’inhibiteurs de la beta-secretase lors du traitement de la maladie d’alzheimer
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
WO2007072201A3 (fr) 3-aminocyclopentanecarboxamides en tant que modulateurs de recepteurs de chimiokine
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
WO2008054698A3 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
WO2005058890A3 (fr) Derives d'hydronopol utilises comme agonistes des recepteurs orl1 humains
WO2006121717A3 (fr) Compositions pour soins de la peau contenant de l'idebenone
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
FR2885491B1 (fr) Traitement de la secheresse keratinique par des glycerides
WO2008013823A3 (fr) Co-cristaux de (2r-trans)-6-chloro-5-[[4-[(4-fluorophényl)méthyl]-2,5-diméthyl-1-pipérazinyl]carbonyl]-n,n,1-triméthyl-alpha-oxo-1h-indole-3-acétamide
NO20090619L (no) Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens
MA31880B1 (fr) Formulations stables d'un derive thiadiazole